Pharmaceutical

Bayer looks to expand Kerendia label to include heart failure

Bayer adds three new Phase III heart failure studies to the Kidney and type 2 diabetes drug, Kerendia, clinical development programme.

Sep 1, 2023 - 20:00
Bayer looks to expand Kerendia label to include heart failure
Bayer adds three new Phase III heart failure studies to the Kidney and type 2 diabetes drug, Kerendia, clinical development programme.
Read the original article

Tags:

Previous Article

NexImmune to lay off over half of its employees

Next Article

Signal: Novo Nordisk market cap higher than Danish GDP due to obesity drugs

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Here’s what’s moving the needle in biotech stocks, in the final quarter of a dismal year

Here’s what’s moving the needle in biotech stocks, in t...

Oct 2, 2023

The stability of $0 premiums in Medicare Advantage

The stability of $0 premiums in Medicare Advantage

Oct 2, 2023

Opinion: The pink ribbon of breast cancer awareness needs a splash of blue for men

Opinion: The pink ribbon of breast cancer awareness nee...

Oct 28, 2023